Employees: 97
Size NIOX (NIOX.L) is a United Kingdom Health Care company (Medical/Nursing Services) with a market value of $325M, the 346th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £61.00 on 18 Nov 2026.
Performance Over six months the shares gained 3.0%, against -4.0% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 3.3% over the last twelve months (peer median +6.0%); the operating margin is 21.9% (peer median 8.0%).
Valuation It trades at 19.8× forward earnings against a peer median of 16.9× (5th most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.7 points above its cost of capital (6.9% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £47.5M | £48.7M | £41.8M | £36.8M | £31.3M |
| Revenue growth | — | +17% | +14% | +18% | — |
| Gross profit | £28.7M | £29.6M | £26.0M | £22.1M | £17.6M |
| EBITDA | £14.7M | £14.8M | £11.9M | £9.00M | £6.40M |
| Net income | £7.00M | £7.00M | £3.70M | £10.7M | £16.1M |
| Free cash flow | £12.5M | £15.6M | £18.0M | £12.1M | £6.70M |
| Capital expenditure | £1.00M | £1.50M | £1.00M | £300,000 | £100,000 |
| Total debt | n/a | £1.00M | £1.50M | £1.10M | £1.00M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NIOX.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.6% | -6.8% | 10th lowest of 21 |
| 6-month return | +3.0% | -4.0% | 7th highest of 20 |
| Distance from 52-week high | -23.8% | -30.8% | 9th highest of 21 |
| Revenue growth (TTM) | +3.3% | +6.0% | 8th lowest of 21 |
| Operating margin | 21.9% | 8.0% | 3rd highest of 21 |
| Forward P/E | 19.8× | 16.9× | 5th most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 3.4% | 6.6% | 6th least demanding of 17 |
| Growth delivered (Del g) | +15.3% | +16.6% | 8th lowest of 17 |
| Hurdle (Req g minus delivered) | -11.9 pp | -12.8 pp | 9th least demanding of 17 |
| ROIC minus cost of capital | +8.7 pp | -2.5 pp | 5th highest of 20 |
| EV / EBITDA | 15.7× | 8.8× | 3rd most expensive of 13 |
| Net debt / EBITDA | -1.1× | 1.6× | 4th least indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NIOX NIOX.L | United Kingdom | $325M | +3% | +3% | 22% | 19.8× | 3.4% | +15.3% |
| Oncology Institute STLN | United States | $326M | n/a | +35% | -3% | n/a | 5.4% | +21.8% |
| Tellgen 300642.SZ | China | $328M | -11% | +5% | 8% | n/a | 18.8% | -5.8% |
| Auna AUNA | United States | $309M | -5% | +17% | 13% | 4.1× | -10.7% | +24.4% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $309M | -4% | +5% | 31% | 9.2× | -13.8% | +15.4% |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $352M | +17% | 0% | -2% | n/a | -14.9% | +9.6% |
| Dr. Agarwal'S Eye Hospital DRAGARWQ.NS | India | $292M | +14% | +20% | 21% | n/a | 19.6% | +27.5% |
| M1 Kliniken M12.DE | Germany | $368M | +1% | -28% | 13% | 16.4× | -5.3% | +17.9% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 4% | 24.6× | 12.3% | -1.5% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 17.4× | 7.3% | +42.6% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 14.7× | 7.8% | +17.7% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 17.8× | 4.3% | +2.6% |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 86.3× | n/a | n/a |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | n/a | n/a | n/a |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | n/a | 5.9% | +3.2% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | n/a | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 10.1× | 10.1% | +94.5% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | n/a | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |